CytRx Reports Highly Statistically Significant Positive Results from its Global Phase 2b Clinical Trial
CytRx, a biopharmaceutical research and development company specializing in oncology, today announced highly positive top-line efficacy results from a multicenter, randomized, open-label global Phase 2b clinical trial. The trial investigated the efficacy and safety of aldoxorubicin compared with doxorubicin in subjects with first-line metastatic, locally advanced or unresectable soft tissue sarcomas (STS). Aldoxorubicin combines the chemotherapeutic agent doxorubicin with a novel linker-molecule that binds specifically to albumin in the blood to allow for delivery of higher amounts of doxorubicin (3½ to 4 times) without the major dose-limiting toxicities seen with administration of doxorubicin alone.
Link to the full Press Release: http://phx.corporate-ir.net/phoenix.zhtml?c=187775&p=irol-newsArticle_print&ID=1883842&highlight=